Protocol for the examination of specimens from patients with malignant pleural mesothelioma: A basis for checklists

Archives of Pathology and Laboratory Medicine

Volumn 123, Issue 1, 1999, Pages 39-44

  Nash, Gerald ^a   Otis, Christopher N ^a   Schramm, Joe ^b  

^a BAYSTATE MEDICAL CENTER   (United States)

^b North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CYTODIAGNOSIS; CLINICAL PROTOCOL; HUMAN; PLEURA FLUID; PLEURA MESOTHELIOMA; REVIEW;

EID: 0032894153     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. Frisman D, McCarthy W, Schleiff P, Buckner S, Nocito J, O'Leary T. Immunocytochemistry in the differential diagnosis of effusions: use of logistic regression to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations. Mod Pathol. 1993;6:179-184.
2. Gaffey M, Mills S, Swanson P, Zarbo R, Shah A, Wick M. Immunoreactivity for Ber-EP4 in adenocarcinomas, adenomatoid tumors and malignant mesotheliomas. Am J Surg Pathol. 1992;16:593-599.
3. Otis CN, Carter D, Cole S, Battifora H. Immunohistochemical evaluation of pleural mesothelioma and pulmonary adenocarcinoma: a bi-institutional study of 47 cases. Am J Surg Pathol. 1987;11:445-456.
4. Sheibani K, Azumi N, Battifora H. Further evidence demonstrating the value of Leu M1 antigen in the differential diagnosis of malignant mesothelioma and adenocarcinoma: an immunohistologic evaluation of 395 cases [abstract]. Lab Invest. 1988;58:84A.
5. Sheibani K, Shin S, Kerzirian J, Weiss L. Ber-EP4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma versus adenocarcinoma. Am J Surg Pathol. 1991;15:779-784.
6. Fleming ID, Cooper JS, Henson DE, et al, eds. AJCC Manual (or Staging of Cancer. 5th ed. Philadelphia, Pa: Lippincott Raven; 1997.
7. Hermanek P, Sobin L. TNM Classification of Malignant Tumours. 4th ed. Berlin, Germany: Springer-Verlag; 1992.
8. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Chest. 1995;108:1122-1128.
9. Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastases in resected lung cancer. J Thorac Cardiovasc Surg. 1978;76:832-839.
10. American Thoracic Society: Clinical staging of primary lung cancer. Am Rev Respir Dis. 1983;127:659-664.